Introduction
Neuroblastoma, which originates from the sympathoadrenal lineage of the neural crest, is one of the most common solid tumors in childhood and has distinct biological properties in different prognostic subsets (Schor, 1999) . For example, tumors in patients less than 1 year of age often regress spontaneously and have a favorable prognosis. In contrast, tumors that occur over 1 year of age display an extensive and metastatic disease at diagnosis, and are often aggressive with an unfavorable prognosis despite an intensive therapy (Brodeur and Nakagawara, 1992) . Each of those subsets shows various distinct genetic features including the ploidy status, MYCN amplification, allelic loss of the distal part of chromosome 1p and the gain of chromosome 17q (Brodeur, 2003) . Additionally, high expression levels of neurotrophin receptors TrkA and TrkB are favorable and unfavorable prognostic indicators of neuroblastomas, respectively (Nakagawara et al., 1993 (Nakagawara et al., , 1994 . Several lines of evidence suggest that the spontaneous regression of the favorable neuroblastomas is attributed at least in part to the developmentally programmed neuronal cell death and/or neuronal differentiation (Nakagawara, 1998) . Indeed, the deprivation of nerve growth factor led to the massive cell death through apoptosis of neuroblastoma cells expressing TrkA (Nakagawara et al., 1993) .
Retinoic acids (RAs), which appear to be involved in vertebrate morphogenesis, are natural and synthetic derivatives of vitamin A (Maden, 2001; McCaffery et al., 2003) , and exert their biological functions through nuclear receptors including RA receptors (RARs) and retinoid X receptors (RXRs) (Lippman and Lotan, 2000) . In response to RA binding, RAR/RXR heterodimers regulate the transcription of a number of target genes by binding to the specific DNA response elements (Balmer and Blomhoff, 2002) . Retinoic acids have antitumor effects on neuroblastoma-derived cell lines accompanied by a marked decrease in the expression levels of MYCN (Thiele et al., 1985) . Studies utilizing cell lines also have revealed that neuroblastoma cell lines exposed to all-trans-RA (ATRA) undergo neuronal differentiation, cell cycle arrest and/or apoptosis (Melino et al., 1997; van Noesel and Versteeg, 2004) . Recent works offer insights into the molecular mechanisms by which ATRA exerts its biological effects on neuroblastomas. All-trans-retinoic acid activates phosphatidylinositol 3 0 -kinase-Akt pathway that plays an important role in neuronal differentiation (Encinas et al., 1999; Lopez-Carballo et al., 2002) , and it reduces the expression levels of MYCN (Thiele et al., 1985) and upregulates the cyclin-dependent kinase (CDK) inhibitor p27 KIP1 in association with the ATRA-induced cell cycle arrest in neuroblastoma cells (Lee et al., 1996; Nakamura et al., 2003) . In addition, certain neuroblastoma cells underwent apoptosis in response to ATRA (Piacentini et al., 1992; Takada et al., 2001; Nagai et al., 2004) . Consistent with these observations, 13-cis-RA treatment after intensive chemotherapy improved an event-free survival rate of the patients with aggressive neuroblastomas with 17% increase (Villablanca et al., 1995; Matthay et al., 1999) . Although the antitumor effects of RA alone on aggressive neuroblastoma are limited, RA treatment has an advantage that it carries no severe side effects. Thus, it is important to enhance the antitumor effects of RA on neuroblastoma cells, and thereby inducing apoptosis.
In the present study, we have found that the ATRA treatment induces neuronal differentiation in neuroblastoma-derived LA-N-5 and RTBM1 cells, whereas CHP134 and NB-39-nu cells undergo p53-independent apoptotic cell death in response to ATRA. Extensive expression studies revealed that the antiapoptotic Bcl-2 was constitutively expressed at high levels in LA-N-5 and RTBM1 cells, whereas CHP134 and NB-39-nu cells expressed Bcl-2 at extremely low levels. Enforced expression of Bcl-2 in CHP134 cells led to a significant inhibition of the ATRA-mediated apoptosis. In accordance with these results, the treatment with Bcl-2 inhibitor in RTBM1 cells resulted in an increased sensitivity to ATRA. Moreover, two out of 10 sporadic neuroblastomas in primary cultures with undetectable bcl-2 underwent cell death in response to ATRA, whereas seven tumors out of the remaining eight cases expressed high levels of bcl-2. These results suggest that Bcl-2 might be a key regulator for the ATRA-mediated apoptotic cell death in neuroblastomas.
Results

ATRA-induced growth inhibition, differentiation and cell death in human neuroblastoma cell lines
To examine the possible effects of ATRA on growth and viability of neuroblastoma cells, human neuroblastomaderived LA-N-5, RTBM1, CHP134 and NB-39-nu cells were cultured with or without 5 mM of ATRA, and the numbers of viable cells were counted at the indicated time points after the exposure to ATRA. As shown in Figure 1a , ATRA effectively inhibited proliferation of these neuroblastoma cells. Among them, the growth of CHP134 and NB-39-nu cells was much more suppressed in the presence of ATRA. To monitor morphological changes induced by ATRA, ATRA-treated cells were checked by phase-contrast microscopy. As shown in Figure 1b , a neurite outgrowth was evident in ATRAtreated LA-N-5, RTBM1 and CHP134 cells, whereas it was marginal in NB-39-nu cells. Of note, ATRAinduced cell death was detectable in CHP134 and NB-39-nu cells, but not in LA-N-5 and RTBM1 cells. To confirm whether ATRA could induce the apoptotic cell death in CHP134 and NB-39-nu cells, we examined the changes in the number of cells with sub-G1 DNA content in response to ATRA. As shown in Figure 1c and d, the flow cytometric analysis revealed that the number of CHP134 cells with sub-G1 DNA content was significantly increased in response to ATRA. Similarly, ATRA promoted the apoptotic cell death in NB-39-nu cells, albeit to a lesser degree than CHP134 cells. Under our experimental conditions, ATRA failed to induce the apoptotic cell death in LA-N-5 and RTBM1 cells (data not shown).
ATRA-induced apoptotic cell death in neuroblastoma cells
To elucidate the molecular mechanism(s) underlying the ATRA-mediated apoptotic cell death in neuroblastoma cells, we examined whether the procaspases could be proteolytically cleaved to be activated in response to ATRA. To this end, whole-cell lysates prepared from the indicated neuroblastoma cells exposed to 5 mM of ATRA for 0, 2, 4 and 6 days were subjected to immunoblotting with the indicated antibodies. As shown in Figure 2a , the time-dependent proteolytic cleavage of caspase-9 and caspase-3 was observed in CHP134 and NB-39-nu cells, but not in LA-N-5 and RTBM1 cells. Consistent with these results, one of the physiological substrates of the activated caspase-3, poly-ADP-ribose polymerase (PARP), was cleaved in ATRA-treated CHP134 and NB-39-nu cells. In a good agreement with the previous observations showing that caspase-8 is epigenetically silenced in a high percentage of neuroblastoma cells (Teitz et al., 2000; van Noesel et al., 2003) , caspase-8 was undetectable in LA-N-5, RTBM1 and CHP134 cells. In contrast, NB-39-nu cells expressed a large amount of procaspase-8. Procaspase-12, which is involved in the endoplasmic reticulum-stress-induced apoptosis (Nakagawa et al., 2000; Morishima et al., 2002) , was readily detectable in all of the neuroblastoma cell lines that we examined, and did not respond to ATRA. Under our experimental conditions, ATRA had negligible effects on proteolytic cleavage of caspase-8 and caspase-12 (data not shown).
As caspase-9 is activated in response to the cytoplasmic release of cytochrome c from mitochondria, leading to the activation of caspase-3 (Degterev et al., 2003) , we sought to examine whether cytochrome c could be released in response to ATRA. To this end, CHP134 cells were treated with 5 mM of ATRA or left untreated, and cells were incubated with the antibody against cytochrome c or with the control immunoglobulin (Ig)G. Cell nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). Microscopic images demonstrated that cytochrome c staining displays a punctuate that cytochrome c release from mitochondria might play an important role in ATRA-induced apoptotic cell death in neuroblastoma cells.
As the neuroblastoma cell lines that we examined carry wild-type p53 (data not shown), we investigated whether p53 could contribute to the ATRA-mediated apoptotic cell death. For this purpose, whole-cell lysates prepared from the indicated neuroblastoma cells exposed to 5 mM of ATRA for 0, 2, 4 and 6 days were processed for immunoblotting with the indicated antibodies. As shown in Figure 2c , the amounts of p53 remained unchanged or slightly decreased after ATRA treatment. In accordance with these results, ATRA had undetectable effects on the expression levels of p53-responsible Bax, Puma and p21
WAF1
, which are implicated in the p53-dependent apoptosis and/or cell cycle arrest (Culmsee and Mattson, 2005) . In addition, ATRA failed to induce the phosphorylation of p53 at Ser-15 (data not shown). Thus, it is likely that ATRA-mediated apoptotic cell death in neuroblastoma cells may be regulated in a p53-independent manner.
Differential expression of antiapoptotic Bcl-2 in neuroblastoma cells
To investigate the regulatory mechanisms of apoptotic response to ATRA in neuroblastoma cells, we examined the expression levels of Bcl-2 family proteins, which directly control the mitochondrial pathway of apoptosis. It is worth noting that antiapoptotic Bcl-2 was constitutively expressed at high levels in LA-N-5 as well as RTBM1 cells, whereas CHP134 and NB-39-nu cells expressed Bcl-2 at extremely low levels ( Figure 3a) . Antiapoptotic Bcl-x L was expressed at low levels in all cell lines examined. In accordance with the previous observations showing that proapoptotic Bim and Bmf are highly expressed in neuronal cells (Puthalakath et al., 2001; Okuno et al., 2004; Shi et al., 2004) , Bim and Bmf were expressed at high levels in all of the cell lines that we examined, but their expression levels remained unchanged in the presence of ATRA.
To determine whether Bcl-2 could contribute to the acquisition of the ATRA-resistant phenotype of neuroblastoma cells, CHP134 cells were transfected with the expression plasmid for Bcl-2 or with the empty plasmid, and their sensitivity to ATRA was examined by flow cytometry. As shown in Figure 3b , Bcl-2 was successfully overexpressed in CHP134 cells as examined by immunoblotting. Interestingly, enforced expression of Bcl-2 inhibited the ATRA-mediated proteolytic cleavage of caspase-3. Consistent with these results, flow cytometric analysis demonstrated that ectopic expression of Bcl-2 significantly reduced the number of cells with sub-G1 DNA content induced by ATRA treatment ( Figure  3c and d), suggesting that Bcl-2 might play a critical role in the regulation of apoptotic cell death in neuroblastoma cells.
To further confirm this possibility, we examined the effects of the Bcl-2 inhibitor HA14-1 (Wang et al., 2000) on the ATRA-mediated apoptotic response of neuroblastoma cells. RTBM1 cells were treated with 5 mM of ATRA or left untreated for 6 days, and then incubated in the presence or absence of HA14-1 (15, 30 or 50 mM) for 3 h. Phase-contrast microscopic analysis showed that the incubation with ATRA followed by HA14-1 treatment significantly enhanced the apoptotic response of RTBM1 cells, whereas HA14-1 treatment alone increased the number of apoptotic cells to a lesser degree (Figure 4a) . Similar results were also obtained by flow cytometric analysis (Figure 4b and c) . To examine whether the ATRA-mediated apoptosis in RTBM1 cells induced by HA14-1 treatment could be associated with the activation of the mitochondria-dependent apoptotic pathway, we performed immunoblot analysis. As shown in Figure 4d , HA14-1 treatment at 30 mM or less did not promote the activation of caspase-9 and caspase-3, whereas a small amount of the cleaved caspase-9 and caspase-3 were detectable in RTBM1 cells exposed to 50 mM of HA14-1 alone. Intriguingly, pre-treatment of RTBM1 cells with ATRA enhanced the proteolytic cleavage of caspase-9 and caspase-3 induced by HA14-1 at a final concentration of 50 mM.
To ask whether Bcl-2 could play an important role in ATRA-mediated apoptotic response in primary neuroblastomas, 10 sporadically found neuroblastomas were subjected to both primary culture and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis for bcl-2. In five cases, ATRA treatment induced strong outgrowth of neurites as compared with control culture (Figure 5a, left) . In the other three cases, ATRA had undetectable effects (data not shown). It is worth noting that many cells underwent cell death after ATRA treatment in the remaining two cases (Figure 5a, right) . We also examined the expression levels of bcl-2 of these 10 primary neuroblastoma samples and four neuroblastoma-derived cell lines by RT-PCR. LA-N-5 and RTBM1 cells abundantly expressed bcl-2, whereas CHP134 and NB-39-nu did not (Figure 5b) , which was consistent with immunoblotting as shown in Figure 3a . Of particular interest, RT-PCR analysis revealed that two primary cases that underwent cell death in response to ATRA (N-9 and N-10) expressed bcl-2 at undetectable levels ( Figure 5c ). In a sharp contrast, the expression of bcl-2 was detected in the remaining cases, except N-3. Taken together, our present results strongly suggest that Bcl-2 is a key regulator for ATRA-mediated apoptotic cell death in neuroblastoma cells.
Discussion
Retinoic acid is one of the potent antitumor agents that has been used successfully to treat certain human tumors including neuroblastomas (Freemantle et al., 2003) . Indeed, neuroblastoma patients treated with RA have increased survival rate without severe side effects (Villablanca et al., 1995; Matthay et al., 1999) . Accumulating evidences suggest that RA plays an important role in the regulation of neuroblastoma apoptosis as well as differentiation (Melino et al., 1997; van Noesel and Versteeg, 2004) . However, certain neuroblastomas display an RA-resistant phenotype (Reynolds and Lemons, 2001) . To further improve the therapeutic effects of RA on neuroblastomas, it is necessary to clarify the detailed molecular mechanisms underlying the RA-mediated neuroblastoma differentiation and/or apoptosis. In the present study, we have found that ATRA causes growth suppression and subsequent neuronal differentiation in human neuroblastoma-derived LA-N-5, RTBM1, CHP134 and NB-39-nu cells to various degrees. Among them, CHP134 and NB-39-nu cells, which express antiapoptotic Bcl-2 at extremely low levels, underwent p53-independent apoptotic cell death in response to ATRA. In contrast, LA-N-5 and RTBM1 cells abundantly expressed Bcl-2, and we did not detect apoptotic cell death upon ATRA treatment. Enforced expression of Bcl-2 in CHP134 cells inhibited the ATRA-mediated apoptosis, and HA14-1-mediated inhibition of the endogenous Bcl-2 in RTBM1 cells enhanced the ATRA-dependent apoptotic cell death. Moreover, studies using primary neuroblastoma tissues showed that ATRA had toxic effect on two out of 10 primary cultures, and these ATRA-sensitive tumors did not express bcl-2. Thus, it is likely that antiapoptotic Bcl-2 plays a crucial role in the regulation of the ATRA-mediated apoptotic response in neuroblastomas.
Our present study revealed that neuroblastoma cells can be divided into two groups with respect to the ATRA-induced apoptotic response. CHP134 and NB-39-nu cells underwent apoptotic cell death in response to ATRA, whereas LA-N-5 and RTBM1 cells did not. Consistent with the mitochondria-dependent intrinsic apoptotic pathway of caspase activation (Degterev The indicated neuroblastoma cell lines were cultured in standard culture medium containing all-trans retinoic acid (ATRA) at a final concentration of 5 mM. At the indicated time points after the treatment with ATRA, whole-cell lysates were prepared, and analysed by immunoblotting with the antibodies against the indicated Bcl-2 family proteins. Actin expression was examined as a loading control (bottom). (b) Overexpression of Bcl-2. CHP134 cells were transiently transfected with the expression plasmid for Bcl-2 or with the empty plasmid. Twelve hours after the transfection, cells were treated with or without 5 mM ATRA, and incubated for additional 3 or 6 days. Whole-cell lysates were prepared, and the expression levels of Bcl-2 (top) and the amounts of the cleaved caspase-3 (middle) were examined by immunoblotting. Actin is shown as a control for protein loading (bottom). (c and d) Flow cytometry. CHP134 cells were transiently transfected as described in (b). At the indicated time periods after the treatment with ATRA, cells were collected, fixed and stained with PI. The DNA content of the cells was examined by flow cytometry. Representative results on day 6 are shown in (c). The number of cells with sub-G1 DNA content was counted in triplicate (d). *Po0.01.
Retinoic acid-induced apoptosis in neuroblastoma H Niizuma et al et al., 2003) , ATRA treatment in CHP134 cells caused a cytoplasmic release of the mitochondrial inter-membrane protein cytochrome c, and a sequential proteolytic cleavage of caspase-9, caspase-3 and its physiological substrate PARP. Similar results were obtained in NB-39-nu cells. Our previous observation also demonstrated that activation and nuclear translocation of caspases were associated with prognosis of primary neuroblastomas (Nakagawara et al., 1997) . Therefore, the molecular mechanism(s) of RA-induced activation of caspases in neuroblastoma cells needs to be clarified.
In response to a variety of apoptotic stimuli, p53 is induced to be stabilized and subsequently transactivates a number of proapoptotic genes that encode Bcl-2 Retinoic acid-induced apoptosis in neuroblastoma H Niizuma et al family proteins including Bax (Culmsee and Mattson, 2005) . It has been well documented that Bax acts on the mitochondria to induce mitochondrial permeability transition, and thereby regulating the cytoplasmic release of cytochrome c (Antonsson, 2001) . Neuroblastoma cell lines that we examined in this study carry wildtype p53. Under our experimental conditions, however, we could not detect the ATRA-mediated upregulation of the endogenous p53 as well as Bax. Similarly, the p53-responsible p21 WAF1 and proapoptotic Puma were not accumulated in response to ATRA. As described (Nikolaev et al., 2003) , p53 might not be functional in neuroblastoma cells due to its abnormal cytoplasmic retention. Consistent with this notion, p53 was predominantly expressed in the cytoplasm of neuroblastoma cells examined in this study (data not shown). We have previously shown that cytoplasmic p53 is translocated into the nucleus of CHP134 cells in response to ATRA (Takada et al., 2001) ; however, our present results suggest that translocated p53 was not functional. Indeed, it is reported that p53 in neuroblastoma cells is not functional even after its enforced translocation into the nucleus (Ostermeyer et al., 1996) . Thus, it is likely that the ATRA-mediated apoptotic cell death in neuroblastoma cells is regulated in a p53-independent manner.
Among other regulators of mitochondrial pathway of apoptosis, Bcl-2 family proteins are critical determinants of mitochondrial membrane potential, which controls the cytoplasmic release of cytochrome c from mitochondria and thereby regulating apoptotic cell death (Cory et al., 2003) . They are divided into two subfamilies based on their biological roles. Antiapoptotic subfamily includes Bcl-2 and Bcl-x L and proapoptotic subfamily includes Bax, Bim and Bmf. The balance between these two groups determines the fate of cells. Antiapoptotic Bcl-2 is one of the most important members that inhibits the mitochondria-dependent apoptotic pathway triggered by diverse cytotoxic agents through blocking mitochondrial permeability transition. Indeed, the upregulation of Bcl-2 was associated with the drug-resistant phenotype of certain human tumors (Dole et al., 1994; Lombet et al., 2001) . Most intriguingly, our expression studies revealed that antiapoptotic Bcl-2 was constitutively overexpressed in LA-N-5 and RTBM1 cells, whereas its expression levels were extremely low in CHP134 and NB-39-nu cells. In response to ATRA, Bcl-2 was slightly induced to be accumulated in NB-39-nu cells; however, it was maintained at extremely low levels in CHP134 cells. Furthermore, two primary neuroblastomas on which ATRA had toxic effect in primary culture did not express bcl-2, similar to CHP134 and NB-39-nu cells. Interestingly, ATRA induced differentiation in five cases and had undetectable effects on three cases, but cell death was induced in two cases. Considering that RA treatment contributed to survival of 17% of patients with aggressive neuroblastomas (Matthay et al., 1999) , our present results using primary neuroblastomas seem to be reliable. Taken together, it is likely that ATRA potentially have toxic effect on certain neuroblastoma cells (both primary cells and cell lines) that express little Bcl-2. Our current results also revealed that enforced expression of Bcl-2 in CHP134 cells inhibited the ATRA-mediated apoptosis in association with the activation of caspase-3. Furthermore, ATRA treatment of RTBM1 cells followed by HA14-1 exposure underwent apoptotic cell death through mitochondrial pathway. These observations also support the importance of Bcl-2 in the regulation of apoptotic response of neuroblastoma cells to RA.
Although it is still unclear whether the expression levels of Bcl-2 could be correlated with the prognosis of neuroblastoma patients (Romani and Lu, 1994; Gallo et al., 2003; Abel et al., 2005) , it is possible that Bcl-2 plays a key role at least in part in the regulation of ATRA-mediated apoptotic cell death in neuroblastoma cells. In this connection, the antisense RNA-mediated knockdown of the endogeneous Bcl-2 has been employed to treat certain tumors (Kim et al., 2004) . Recently, a novel Bcl-2 inhibitor that has an antitumor effect on solid tumors has been developed (Oltersdorf et al., 2005) . Based on our present findings, the combination of RA with Bcl-2-specific inhibitor might provide a novel therapeutic strategy for the treatment of neuroblastomas, instead of the classical chemotherapy that frequently has multi-organ side effects. and fresh-frozen tissues of primary neuroblastomas (c), and subjected to RT-PCR using specific primers for bcl-2. N-1 to N-10 indicates the case numbers, and the effects of ATRA on primary cultures are described at the bottom of this panel. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression is shown as an internal control.
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Materials and methods
Cell lines and transfection
Human neuroblastoma-derived cell lines, including LA-N-5, RTBM1, CHP134 and NB-39-nu, were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin (50 U/ml) and streptomycin (50 mg/ml) at 371C in a humidified atmosphere of 5% CO 2 in the air. For transfection, CHP134 cells were transfected with the expression plasmid encoding human Bcl-2 or with the empty plasmid by electroporation using a Nucleofector (Amaxa Biosystems, Koeln, Germany) according to the manufacturer's protocol.
Reagents
All-trans retinoic acid was purchased from Sigma (St Louis, MO, USA) dissolved in dimethylsulfoxisde (DMSO) at a final concentration of 5 mM, and kept at À801C. Bcl-2 inhibitor HA14-1 was purchased from Sigma, dissolved in DMSO as a 10 mM stock solution and stored at À201C. All reagents were of the highest quality available.
Proliferation assay LA-N-5 and RTBM1 cells were plated in triplicate at a density of 1 Â 10 5 per well in 12-well culture plates. CHP134 and NB-39-nu cells were seeded in triplicate at a density of 1 Â 10 4 in 12-well plates. Twelve hours after seeding the cells, cells were treated with ATRA at a final concentration of 5 mM or left untreated, and medium was replaced every 2 days. At the indicated time points after the treatment with ATRA, cells were trypsinized and number of viable cells was directly scored by using the hemocytometer.
Flow cytometric analysis Cells were exposed to the indicated concentration of ATRA. At the indicated time points after the treatment with ATRA, cells were collected by brief centrifugation, and fixed with 70% ethanol at À201C. The cells were washed with phosphatebuffered saline (PBS), resuspended in phosphate-citrate buffer (4 mM citric acid, 200 mM Na 2 HPO 4 ) and kept at room temperature for 15 min. The cells were then centrifuged and resuspended in a solution containing 40 mg/ml of propidium iodide and 0.05% RNase A, and incubated in the dark for 30 min. Before performing flow cytometric analysis, cells were filtered through a 40-mm nylon mesh. DNA content was analysed by FACScan flow cytometer (Becton Dickinson, Oxford, UK).
Immunoblot analysis
Cells were washed twice with ice-cold PBS, lysed in a sodium dodecyl sulfate (SDS)-sample buffer containing 10% glycerol, 5% b-mercaptoethanol, 2.3% SDS and 62.5 mM Tris-HCl, pH 6.8, and then boiled for 3 min. The protein concentrations were determined using Bio-Rad protein assay dye reagent (Bio-Rad Laboratories, Hercules, CA, USA). Bovine serum albumin (BSA) was used as a standard. Aliquots (20 mg) of whole-cell lysates were separated by SDS-polyacrylamide gel electrophoresis and electrophoretically transferred onto polyvinylidene difluoride membranes (Immobilon-P, Millipore, Bedford, MA, USA). The membranes were blocked with 0.3% non-fat milk in Tris-buffered saline containing 0.1% Tween-20 and incubated with appropriate primary antibodies at room temperature for 1 h followed by incubation with the horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology Inc., Beverly, MA, USA). Immunoreactive bands were visualized by using ECL system (Amersham Biosciences, Uppsala, Sweden). The primary antibodies used Immunofluorescent staining CHP134 cells were grown on coverslips in standard culture medium in the presence or absence of 5 mM of ATRA for 4 days. Cells were washed with ice-cold PBS, fixed with 3.7% formaldehyde in PBS for 30 min, permeabilized with 0.2% Triton X-100 in PBS for 5 min and then blocked with 3% BSA in PBS for 1 h at room temperature. After blocking, cells were incubated with a monoclonal antibody against cytochrome c (6H2.B4; BD PharMingen, San Jose, CA, USA) or with a normal mouse IgG for 1 h at room temperature, followed by the incubation with fluorescein isothiocyanate-conjugated secondary antibody against mouse IgG (Santa Cruz Biotechnology). The cell nuclei were stained with DAPI. The coverslips were mounted onto glass slides, and the stained cells were examined by using a confocal laser scanning microscope (Olympus).
Primary culture RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, penicillin (50 U/ml), streptomycin (50 mg/ml) and 100 mg/ml of OPI (Sigma) was used as a standard medium for primary culture. Primary tumor cells were prepared from fresh human neuroblastoma tissues by a standard method. A total of 5 Â 10 5 cells of each sample were resuspended in 1 ml of the standard medium, and seeded on 24-well tissue culture plates precoated with collagen. The cells were treated with or without ATRA at a final concentration of 5 mM for at least 2 weeks. The effects of ATRA on the growth and neurite extension of primary neuroblastoma cells were examined by phase-contrast microscope.
RNA extraction and RT-PCR Total RNA was prepared from fresh-frozen tissues of primary neuroblastomas or cultured cells by using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Total RNA (2 mg) was reverse transcribed by using random primers and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). The resultant cDNA was subjected to PCR-based amplification. The oligonucleotide primers used in this study were as follows: bcl-2, 5 0 -GAGGATTGTGGCCTTCTTTG-3 0 (forward) and 5 0 -ACAGTTCCACAAAGGCATCC-3 0 (reverse), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 5 0 -ACCTGA CCTGCCGTCTAGAA-3 0 (forward) and 5 0 -TCCACCACCC TGTTGCTGTA-3 0 (reverse). PCR products were electrophoretically separated on 1% neutral agarose gels and visualized by ethidium bromide staining.
